Main Session
Sep
30
SS 36 - GI 3: Liver - Checking in on Inhibitors, inSPECTing Liver Function, and Making Progress Oligo-ly
309 - Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study
Presenter(s)
Hong-zhi Wang, MD - Peking University Cancer Hospital and Institute, Beijing, Beijing